Tyra announces initial data from Phase II SURF302 trial of dabogratinib

​

Tyra Biosciences has reported initial data from its Phase II SURF302 clinical trial of the oral drug dabogratinib in FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder cancer (LG IR NMIBC) patients.

The post Tyra announces initial data from Phase II SURF302 trial of dabogratinib appeared first on Hospital Management.

 

Back to the Featured Stories
Tyra announces initial data from Phase II SURF302 trial of dabogratinib

Featured Stories

Hyperfine concludes Contrast PMR study enrolment for Swoop MRI system
Arrowhead reports top-line results in mixed hyperlipidaemia trial
Eli Lilly and QurCan sign genetic medicine deal
BRAINBox and Prolight sign supply agreement for concussion tests
Taiho, Cullinan report improved PFS in Phase III NSCLC trial

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us